Search This Blog

Friday, August 30, 2019

Alexion down on Amgen challenge of Soliris patents

Alexion Pharmaceuticals (NASDAQ:ALXN) is down 8% premarket on modest volume in reaction to Amgen’s (NASDAQ:AMGN) challenge of three patents covering top seller Soliris (eculizumab).
The USPTO should announce its decision in about a year.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.